These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
329 related articles for article (PubMed ID: 15637150)
1. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Ungerstedt JS; Sowa Y; Xu WS; Shao Y; Dokmanovic M; Perez G; Ngo L; Holmgren A; Jiang X; Marks PA Proc Natl Acad Sci U S A; 2005 Jan; 102(3):673-8. PubMed ID: 15637150 [TBL] [Abstract][Full Text] [Related]
2. Changes in the Expression of TBP-2 in Response to Histone Deacetylase Inhibitor Treatment in Human Endometrial Cells. Kim HI; Seo SK; Chon SJ; Kim GH; Lee I; Yun BH Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572677 [TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Marks PA; Jiang X Cell Cycle; 2005 Apr; 4(4):549-51. PubMed ID: 15738652 [TBL] [Abstract][Full Text] [Related]
4. Suberoylanilide hydroxamic acid-induced HeLa cell death is closely correlated with oxidative stress and thioredoxin 1 levels. You BR; Park WH Int J Oncol; 2014 May; 44(5):1745-55. PubMed ID: 24626405 [TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors promote apoptosis and senescence in human mesenchymal stem cells. Di Bernardo G; Squillaro T; Dell'Aversana C; Miceli M; Cipollaro M; Cascino A; Altucci L; Galderisi U Stem Cells Dev; 2009 May; 18(4):573-81. PubMed ID: 18694296 [TBL] [Abstract][Full Text] [Related]
6. Suberoylanilide hydroxamic acid induces thioredoxin1-mediated apoptosis in lung cancer cells via up-regulation of miR-129-5p. You BR; Park WH Mol Carcinog; 2017 Dec; 56(12):2566-2577. PubMed ID: 28667779 [TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Häcker S; Dittrich A; Mohr A; Schweitzer T; Rutkowski S; Krauss J; Debatin KM; Fulda S Oncogene; 2009 Sep; 28(35):3097-110. PubMed ID: 19597472 [TBL] [Abstract][Full Text] [Related]
8. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Dai Y; Rahmani M; Dent P; Grant S Mol Cell Biol; 2005 Jul; 25(13):5429-44. PubMed ID: 15964800 [TBL] [Abstract][Full Text] [Related]
9. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386 [TBL] [Abstract][Full Text] [Related]
10. Thioredoxin in cancer--role of histone deacetylase inhibitors. Marks PA Semin Cancer Biol; 2006 Dec; 16(6):436-43. PubMed ID: 17095247 [TBL] [Abstract][Full Text] [Related]
11. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Rahmani M; Reese E; Dai Y; Bauer C; Payne SG; Dent P; Spiegel S; Grant S Cancer Res; 2005 Mar; 65(6):2422-32. PubMed ID: 15781658 [TBL] [Abstract][Full Text] [Related]
12. The role of oxidative stress in apoptosis induced by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in human colon adenocarcinoma HT-29 cells. Portanova P; Russo T; Pellerito O; Calvaruso G; Giuliano M; Vento R; Tesoriere G Int J Oncol; 2008 Aug; 33(2):325-31. PubMed ID: 18636153 [TBL] [Abstract][Full Text] [Related]
13. The levels of HDAC1 and thioredoxin1 are related to the death of mesothelioma cells by suberoylanilide hydroxamic acid. You BR; Park WH Int J Oncol; 2016 May; 48(5):2197-204. PubMed ID: 26936390 [TBL] [Abstract][Full Text] [Related]
14. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Butler LM; Zhou X; Xu WS; Scher HI; Rifkind RA; Marks PA; Richon VM Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11700-5. PubMed ID: 12189205 [TBL] [Abstract][Full Text] [Related]
15. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells. Ruefli AA; Bernhard D; Tainton KM; Kofler R; Smyth MJ; Johnstone RW Int J Cancer; 2002 May; 99(2):292-8. PubMed ID: 11979447 [TBL] [Abstract][Full Text] [Related]
16. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. Butler LM; Liapis V; Bouralexis S; Welldon K; Hay S; Thai le M; Labrinidis A; Tilley WD; Findlay DM; Evdokiou A Int J Cancer; 2006 Aug; 119(4):944-54. PubMed ID: 16550602 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma. Dalgard CL; Van Quill KR; O'Brien JM Clin Cancer Res; 2008 May; 14(10):3113-23. PubMed ID: 18483379 [TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio. Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472 [TBL] [Abstract][Full Text] [Related]
19. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692 [TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. Denlinger CE; Rundall BK; Jones DR J Thorac Cardiovasc Surg; 2004 Nov; 128(5):740-8. PubMed ID: 15514602 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]